Developer docs
API playgroundTry for free, no card

Search company profiles

TOBY

Full company profile

uuid0002lhd

Namestring
TOBY
Legal namestring
TOBY, Inc.
Websiteurl
toby.health
Company typeenum
Private
Founded yearint
2023
Descriptiontext

TOBY, Inc. is a pre-commercial biotechnology company developing a urine-based diagnostic platform that uses volatolomics — the analysis of volatile organic compounds (VOCs) in urine — combined with mass spectrometry and proprietary AI/ML algorithms to detect early-stage disease, beginning with cancer. The company has assembled three indication-specific tests: a bladder cancer detection test (FDA Breakthrough Device Designation, June 2025), a Multi-Cancer Early Detection (MCED) test designed to identify more than ten cancers from a single urine sample and covering over 60% of global cancer cases (Breakthrough Designation, April 2026 — the first ever awarded to a urine-based MCED technology), and an Alzheimer's disease diagnostic test (Breakthrough Designation, May 2026). The underlying TOBY™ Platform / Volatomic Insights architecture ingests a urine sample, runs mass spectrometry to read molecular signatures, and applies machine learning to determine whether the sample is disease-positive or negative.

The business model is diagnostic testing services targeting healthcare providers, health systems, and adults aged 50+, with planned distribution through hospitals and clinical laboratories once FDA approval and reimbursement are secured. TOBY has not yet launched a commercial product, has no publicly disclosed pricing, and is generating no revenue. The company was founded in 2023 by Matthew Laskowski (CEO) and Dragan Sebišanović (CSO), is headquartered in Austin, Texas with operations in Boston, and has 1-10 employees. Capital structure consists of a ~$1.4M disclosed equity round (February 2025) plus non-dilutive support from the Massachusetts AI Health Innovation Grant, the Mayo Clinic & ASU MedTech Accelerator (2025 cohort), Nashville Entrepreneur Center's Project Healthcare (HCA Healthcare Scholar), LifeX, and MassChallenge. The board and advisory bench includes diagnostic and healthcare operators such as Dan Collins (founder of GenesisCare) and Matthew Collier (ex-McKinsey/Bain/Accenture diagnostics CEO), with clinical evidence generation led by a Duke University prostate cancer study.

Short descriptiontext

TOBY is a pre-commercial biotechnology company developing AI-powered, urine-based diagnostic tests for early cancer and Alzheimer's detection, using mass spectrometry and proprietary machine learning to analyze volatile organic compound signatures for healthcare systems and at-risk adults.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew City, United States
HQ citystring
New City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
urine-based diagnostics, cancer screening, mass spectrometry analysis, AI medical diagnostics, volatolomics platform
Industry2 codes
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)
NAICS code2 codes
  • Medical Laboratories621511
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Cancer Diagnostics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Diagnostic Testing Services
TypeOne Time License
Description

TOBY generates revenue through urine-based diagnostic tests that detect cancer and other diseases. The test requires only a single urine sample, offering an alternative to blood-based screening approaches. The company is working toward FDA approval and reimbursement to enable commercial launch.

toby.health
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

TOBY develops a urine-based diagnostic platform that combines mass spectrometry with proprietary artificial intelligence to analyze volatile organic compounds (VOCs) in urine for early detection of cancer and other diseases. The company's three FDA Breakthrough Device designated products — Multi-Cancer Early Detection (MCED), bladder cancer detection, and Alzheimer's disease diagnosis — analyze urinary molecular signatures from a single non-invasive sample to identify disease patterns often before symptoms appear. The platform is positioned as a low-cost, scalable, non-invasive alternative to blood-based or imaging-based screening.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Detects over 10 cancers from a single urine sample
+2 more records
Product overview1 text field

TOBY is a biotechnology company offering a unified urine-based diagnostic platform (TOBY™ Platform/Volatomic Insights) using volatolomics, mass spectrometry, and AI. The platform comprises three core products: the Multi-Cancer Early Detection (MCED) Test designed to detect multiple cancers from a single urine sample, the TOBY Test for Bladder Cancer using gas chromatography-mass spectrometry and AI for cancer risk scoring, and the TOBY Alzheimer's Test using urinary VOC patterns for cognitive evaluation. All products analyze volatile organic compounds (VOCs) in urine through mass spectrometry, with proprietary AI interpreting molecular signatures to detect disease patterns. The platform represents over 60% of global cancer cases detection capability.

Product and service4 records
1TOBY Alzheimer's Test
CategoryNeurological Diagnostics
Description

Urine-based diagnostic test that analyzes urinary volatile organic compound (VOC) patterns through mass spectroscopy and machine learning algorithms to aid in diagnosis of Alzheimer's disease in adults aged 50 and older presenting with signs and symptoms of cognitive impairment.

2TOBY Multi-Cancer Early Detection (MCED) Test
CategoryCancer Diagnostics
Description

Urine-based multi-cancer early detection test that analyzes volatile organic compounds (VOCs) in urine using mass spectrometry and machine learning to identify cancer-associated molecular patterns from a single non-invasive sample, covering more than ten cancers representing over 60% of global cancer cases.

3TOBY Test for Bladder Cancer
CategoryCancer Diagnostics
Description

AI-powered urine test for early bladder cancer detection that uses gas chromatography-mass spectrometry and proprietary AI to generate real-time cancer risk scores from volatile organic compounds in a single urine sample.

4TOBY™ Platform
CategoryDiagnostic Platform / Technology
Description

Volatolomics platform that mimics the disease-sensing power of dogs using urine signatures and AI for fast, non-invasive screening and diagnostics, combining advanced mass spectrometry, machine learning, and privacy-first architecture.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Flagship program of Mayo Clinic and Arizona State University Alliance for Health Care supporting early-stage health tech companies with expert mentoring, personalized strategy, and clinical validation opportunities. TOBY completed participation in the 2025 cohort (selected from global pool of applicants).

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-23
Description

Healthcare accelerator backed by Nashville Entrepreneur Center helping healthcare startups scale by connecting them with customers, capital, and industry experts. TOBY completed this four-month program as an HCA Healthcare Scholar, gaining strategic mentorship and industry connections.

3LifeX Life Sciences Accelerator
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Supports early-stage healthcare companies preparing to bring science-driven technologies to market, with focus on clinical and operational readiness. TOBY participated in this pre-commercialization accelerator.

toby.health
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Globally competitive, equity-free accelerator for high-impact ventures. TOBY was selected from over 1,300 startups for early-stage support.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Duke-led prostate cancer study using TOBY's urine volatilomic technology. Preliminary findings were selected for podium presentation at the American Urological Association Annual Meeting and oral presentation at the Focal Therapy Society 2026 meeting. Study explores AI-driven detection of low-PSA prostate cancer and MRI-invisible lesions.

Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

CIC assisted TOBY in software development efforts as part of the Massachusetts AI Health Innovation Grant.

7McDermott Will & Emery
Strategic tierMinorTypeImplementation/ SI/ Consulting Partner
Description

TOBY was selected for McDermott Will & Emery's competitive LEAP Program, gaining elite legal and strategic support for growth in cancer detection.

toby.health
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Freenome is a privately-held multi-cancer early detection company using a blood-based multiomics platform (cell-free DNA, methylation, proteins) combined with AI. It is a direct competitor in the MCED space pursuing similar clinical validation and FDA breakthrough pathways.

TypeDirect peer
Description

C2N Diagnostics pioneered the PrecivityAD blood-based biomarker test for Alzheimer's disease detection. It directly parallels TOBY's FDA Breakthrough-designated Alzheimer's diagnostic test, addressing the same patient population (adults 50+ with cognitive impairment) with a different analyte matrix (blood vs. urine).

TypeBroad incumbent
Description

Guardant Health is an established leader in liquid biopsy oncology diagnostics (Guardant360 CDx, Shield for CRC screening). As a publicly-traded incumbent with deep clinical evidence, regulatory infrastructure, and payer relationships in oncology diagnostics, it is a relevant broad-incumbent peer even though it does not compete in volatolomics or urine-based detection.

TypeBroad incumbent
Description

Exact Sciences is a publicly-traded leader in cancer screening (Cologuard for CRC, Oncotype DX, and now Thrive Earlier Detection MCED after acquisition). It represents the dominant commercial-scale reference point for non-invasive cancer screening commercialization, GTM, and reimbursement.

TypeEmerging player
Description

Universal Diagnostics is developing a blood-based multi-cancer screening test using metabolomics and machine learning, targeting colorectal and other cancers. It is an emerging-stage peer with thematic overlap in early-detection cancer diagnostics using advanced chemistry and AI.

TypeEmerging player
Description

VolitionRx is developing blood-based Nu.Q nucleosome-based biomarker tests for cancer detection and other diseases. It is an emerging-stage peer pursuing diagnostic tests using biomarker-based approaches, although focused on a different molecular analyte than volatolomics.

7GRAIL
TypeDirect peer
Description

GRAIL's Galleri is the leading blood-based multi-cancer early detection (MCED) test, making it the most direct comparable to TOBY's urine-based MCED test in terms of clinical use case (early detection of multiple cancers from a single non-invasive sample) and regulatory positioning (Breakthrough Device Designation + CMS coverage pathway).

TypeDirect peer
Description

Owlstone Medical is the leading volatolomics / breath-based diagnostics company using VOC biomarkers and proprietary chemical sensors for early disease detection including cancer. It is the most scientifically analogous peer to TOBY's urine-VOC platform, sharing the core volatolomics method architecture.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TOBY

Cancer Diagnosticstoby.health

TOBY is a pre-commercial biotechnology company developing AI-powered, urine-based diagnostic tests for early cancer and Alzheimer's detection, using mass spectrometry and proprietary machine learning to analyze volatile organic compound signatures for healthcare systems and at-risk adults.

What TOBY does

TOBY, Inc. is a pre-commercial biotechnology company developing a urine-based diagnostic platform that uses volatolomics — the analysis of volatile organic compounds (VOCs) in urine — combined with mass spectrometry and proprietary AI/ML algorithms to detect early-stage disease, beginning with cancer. The company has assembled three indication-specific tests: a bladder cancer detection test (FDA Breakthrough Device Designation, June 2025), a Multi-Cancer Early Detection (MCED) test designed to identify more than ten cancers from a single urine sample and covering over 60% of global cancer cases (Breakthrough Designation, April 2026 — the first ever awarded to a urine-based MCED technology), and an Alzheimer's disease diagnostic test (Breakthrough Designation, May 2026). The underlying TOBY™ Platform / Volatomic Insights architecture ingests a urine sample, runs mass spectrometry to read molecular signatures, and applies machine learning to determine whether the sample is disease-positive or negative.

The business model is diagnostic testing services targeting healthcare providers, health systems, and adults aged 50+, with planned distribution through hospitals and clinical laboratories once FDA approval and reimbursement are secured. TOBY has not yet launched a commercial product, has no publicly disclosed pricing, and is generating no revenue. The company was founded in 2023 by Matthew Laskowski (CEO) and Dragan Sebišanović (CSO), is headquartered in Austin, Texas with operations in Boston, and has 1-10 employees. Capital structure consists of a ~$1.4M disclosed equity round (February 2025) plus non-dilutive support from the Massachusetts AI Health Innovation Grant, the Mayo Clinic & ASU MedTech Accelerator (2025 cohort), Nashville Entrepreneur Center's Project Healthcare (HCA Healthcare Scholar), LifeX, and MassChallenge. The board and advisory bench includes diagnostic and healthcare operators such as Dan Collins (founder of GenesisCare) and Matthew Collier (ex-McKinsey/Bain/Accenture diagnostics CEO), with clinical evidence generation led by a Duke University prostate cancer study.

TOBY firmographics

Firmographics
Name
TOBY
Legal name
TOBY, Inc.
Website
https://toby.health
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
TOBY is a pre-commercial biotechnology company developing AI-powered, urine-based diagnostic tests for early cancer and Alzheimer's detection, using mass spectrometry and proprietary machine learning to analyze volatile organic compound signatures for healthcare systems and at-risk adults.
Ownership category
akta.pro rank

TOBY industry classification

Industry
Product category
Cancer Diagnostics
NAICS
Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLAGADAF
Molecular & Genetic Testing (PCR/NGS/qPCR)

Keywords

  • Urine-based diagnostics
  • Cancer screening
  • Mass spectrometry analysis
  • AI medical diagnostics
  • Volatolomics platform

Where TOBY is headquartered

Location

Headquarters

HQ city
New City
HQ country
United States
HQ region
North America

Offices2 records

Markets served

TOBY business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Diagnostic Testing Services: TOBY generates revenue through urine-based diagnostic tests that detect cancer and other diseases. The test requires only a single urine sample, offering an alternative to blood-based screening approaches. The company is working toward FDA approval and reimbursement to enable commercial launch.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

TOBY product offering

Product offering

Core offering

TOBY develops a urine-based diagnostic platform that combines mass spectrometry with proprietary artificial intelligence to analyze volatile organic compounds (VOCs) in urine for early detection of cancer and other diseases. The company's three FDA Breakthrough Device designated products — Multi-Cancer Early Detection (MCED), bladder cancer detection, and Alzheimer's disease diagnosis — analyze urinary molecular signatures from a single non-invasive sample to identify disease patterns often before symptoms appear. The platform is positioned as a low-cost, scalable, non-invasive alternative to blood-based or imaging-based screening.

Product overview

TOBY is a biotechnology company offering a unified urine-based diagnostic platform (TOBY™ Platform/Volatomic Insights) using volatolomics, mass spectrometry, and AI. The platform comprises three core products: the Multi-Cancer Early Detection (MCED) Test designed to detect multiple cancers from a single urine sample, the TOBY Test for Bladder Cancer using gas chromatography-mass spectrometry and AI for cancer risk scoring, and the TOBY Alzheimer's Test using urinary VOC patterns for cognitive evaluation. All products analyze volatile organic compounds (VOCs) in urine through mass spectrometry, with proprietary AI interpreting molecular signatures to detect disease patterns. The platform represents over 60% of global cancer cases detection capability.

Differentiator

Problem solved

Functional benefit

Products and services

  • TOBY Alzheimer's Test Urine-based diagnostic test that analyzes urinary volatile organic compound (VOC) patterns through mass spectroscopy and machine learning algorithms to aid in diagnosis of Alzheimer's disease in adults aged 50 and older presenting with signs and symptoms of cognitive impairment.
  • TOBY Multi-Cancer Early Detection (MCED) Test Urine-based multi-cancer early detection test that analyzes volatile organic compounds (VOCs) in urine using mass spectrometry and machine learning to identify cancer-associated molecular patterns from a single non-invasive sample, covering more than ten cancers representing over 60% of global cancer cases.
  • TOBY Test for Bladder Cancer AI-powered urine test for early bladder cancer detection that uses gas chromatography-mass spectrometry and proprietary AI to generate real-time cancer risk scores from volatile organic compounds in a single urine sample.
  • TOBY™ Platform Volatolomics platform that mimics the disease-sensing power of dogs using urine signatures and AI for fast, non-invasive screening and diagnostics, combining advanced mass spectrometry, machine learning, and privacy-first architecture.

Quantifiable outcome

  • Detects over 10 cancers from a single urine sample
  • +2 more outcomes

Companies that use TOBY

Customer profile

Segments3 records

Ideal customer profiles2 records

TOBY technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

TOBY partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • Mayo Clinic & ASU Alliance for Health Care MedTech AcceleratorflagshipStrategic or Co-development Partner · 23 June 2025Flagship program of Mayo Clinic and Arizona State University Alliance for Health Care supporting early-stage health tech companies with expert mentoring, personalized strategy, and clinical validation opportunities. TOBY completed participation in the 2025 cohort (selected from global pool of applicants).
  • Nashville Entrepreneur Center - Project HealthcarecoreStrategic or Co-development Partner · 23 June 2025Healthcare accelerator backed by Nashville Entrepreneur Center helping healthcare startups scale by connecting them with customers, capital, and industry experts. TOBY completed this four-month program as an HCA Healthcare Scholar, gaining strategic mentorship and industry connections.
  • LifeX Life Sciences AcceleratorminorStrategic or Co-development PartnerSupports early-stage healthcare companies preparing to bring science-driven technologies to market, with focus on clinical and operational readiness. TOBY participated in this pre-commercialization accelerator.
  • MassChallengeminorStrategic or Co-development PartnerGlobally competitive, equity-free accelerator for high-impact ventures. TOBY was selected from over 1,300 startups for early-stage support.
  • Duke UniversitycoreStrategic or Co-development PartnerDuke-led prostate cancer study using TOBY's urine volatilomic technology. Preliminary findings were selected for podium presentation at the American Urological Association Annual Meeting and oral presentation at the Focal Therapy Society 2026 meeting. Study explores AI-driven detection of low-PSA prostate cancer and MRI-invisible lesions.
  • Cambridge Innovation Center (CIC)minorImplementation/ SI/ Consulting PartnerCIC assisted TOBY in software development efforts as part of the Massachusetts AI Health Innovation Grant.
  • McDermott Will & EmeryminorImplementation/ SI/ Consulting PartnerTOBY was selected for McDermott Will & Emery's competitive LEAP Program, gaining elite legal and strategic support for growth in cancer detection.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

TOBY competitors and assessment

Company assessment

Direct peers

  • Freenome: Freenome is a privately-held multi-cancer early detection company using a blood-based multiomics platform (cell-free DNA, methylation, proteins) combined with AI. It is a direct competitor in the MCED space pursuing similar clinical validation and FDA breakthrough pathways.
  • C2N Diagnostics: C2N Diagnostics pioneered the PrecivityAD blood-based biomarker test for Alzheimer's disease detection. It directly parallels TOBY's FDA Breakthrough-designated Alzheimer's diagnostic test, addressing the same patient population (adults 50+ with cognitive impairment) with a different analyte matrix (blood vs. urine).
  • GRAIL: GRAIL's Galleri is the leading blood-based multi-cancer early detection (MCED) test, making it the most direct comparable to TOBY's urine-based MCED test in terms of clinical use case (early detection of multiple cancers from a single non-invasive sample) and regulatory positioning (Breakthrough Device Designation + CMS coverage pathway).
  • Owlstone Medical: Owlstone Medical is the leading volatolomics / breath-based diagnostics company using VOC biomarkers and proprietary chemical sensors for early disease detection including cancer. It is the most scientifically analogous peer to TOBY's urine-VOC platform, sharing the core volatolomics method architecture.

Broad incumbents

  • Guardant Health: Guardant Health is an established leader in liquid biopsy oncology diagnostics (Guardant360 CDx, Shield for CRC screening). As a publicly-traded incumbent with deep clinical evidence, regulatory infrastructure, and payer relationships in oncology diagnostics, it is a relevant broad-incumbent peer even though it does not compete in volatolomics or urine-based detection.
  • Exact Sciences: Exact Sciences is a publicly-traded leader in cancer screening (Cologuard for CRC, Oncotype DX, and now Thrive Earlier Detection MCED after acquisition). It represents the dominant commercial-scale reference point for non-invasive cancer screening commercialization, GTM, and reimbursement.

Emerging players

  • Universal Diagnostics: Universal Diagnostics is developing a blood-based multi-cancer screening test using metabolomics and machine learning, targeting colorectal and other cancers. It is an emerging-stage peer with thematic overlap in early-detection cancer diagnostics using advanced chemistry and AI.
  • VolitionRx: VolitionRx is developing blood-based Nu.Q nucleosome-based biomarker tests for cancer detection and other diseases. It is an emerging-stage peer pursuing diagnostic tests using biomarker-based approaches, although focused on a different molecular analyte than volatolomics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

TOBY financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TOBY leadership team

Management profile

Number of profiles

Profiles7 records

TOBY funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TOBY M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TOBY

What does TOBY do?

TOBY develops a urine-based diagnostic platform that combines mass spectrometry with proprietary artificial intelligence to analyze volatile organic compounds (VOCs) in urine for early detection of cancer and other diseases. The company's three FDA Breakthrough Device designated products — Multi-Cancer Early Detection (MCED), bladder cancer detection, and Alzheimer's disease diagnosis — analyze urinary molecular signatures from a single non-invasive sample to identify disease patterns often before symptoms appear. The platform is positioned as a low-cost, scalable, non-invasive alternative to blood-based or imaging-based screening.

Is TOBY a public or private company?

TOBY is a private company. It is classified as venture growth investor backed and is currently operating.

When was TOBY founded?

TOBY was founded in 2023. It employs 11 to 50 people.

Where is TOBY based?

TOBY is headquartered in New City, United States, in the North America region.

How does TOBY make money?

One revenue line is on record: diagnostic Testing Services.

Who are TOBY's main competitors?

Direct peers on record are Freenome, C2N Diagnostics, GRAIL and Owlstone Medical. Broad incumbents are Guardant Health and Exact Sciences. Emerging players are Universal Diagnostics and VolitionRx.

Does TOBY have an API?

No public API is recorded for TOBY.

What industry is TOBY in?

TOBY's product category is Cancer Diagnostics. Its primary akta.pro industry code is HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy), with a secondary code of HLAGADAF, Molecular & Genetic Testing (PCR/NGS/qPCR). Its NAICS code is 621511 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Healthcare IT NewsA new cancer detection test shows promiseToby has developed a machine learning and biomarker analysis technology that enables urine-based multi-cancer detection and has received FDA Breakthrough Device Designation in the United States. The company's CEO Matthew Laskowski discussed the technology's capabilities in an interview. The article provides limited technical detail, functioning more as a preview or teaser for a planned conversation rather than a full report on the technology's performance or clinical data.Mpo-magFDA Breakthrough Designation Granted to Urine-Based Multi-Cancer Early Detection TestTOBY Inc. received FDA Breakthrough Device Designation for its urine-based multi-cancer early detection test. The platform uses spectroscopy and machine learning to detect over 10 cancers from a single sample, building on a prior designation for its bladder cancer test. The company plans to accelerate clinical validation and future regulatory submissions.My Nintendo NewsDeltarune: Chapter 5 launches for Switch and Switch 2 as free update on 24th JuneDeltarune Chapter 5 launches for Nintendo Switch and Switch 2 as a free update on 24th June 2026. The game continues Kris, Susie, and Ralsei's journey to seal the Dark Fountains, featuring action-packed battles and new characters.RAPPLERSM Active Hub leads Philippine pickleball boom with 86 courts nationwideSM Active Hub expanded to 86 pickleball courts across 29 malls in 2026, hosting over 100 tournaments and welcoming nine international players. The initiative includes events like the SM Pickleball Super Series and community activations, with over 130,000 members.Clinical Lab ProductsFDA Grants Breakthrough Designation to Urine-Based Alzheimer’s TestThe FDA granted Breakthrough Device Designation to TOBY Inc's urine-based Alzheimer's disease diagnostic test, which uses urinary volatile organic compound patterns analyzed through mass spectroscopy and machine learning algorithms to aid in diagnosis. The test is intended for adults aged 50 and older showing signs of cognitive impairment and represents the company's third FDA Breakthrough Device Designation. TOBY plans to continue clinical validation studies and work with the FDA toward future regulatory submissions.PR NewswireTOBY Receives FDA Breakthrough Device Designation for Its Urine-Based Alzheimer's Disease Diagnostic TestThe FDA granted Breakthrough Device Designation to TOBY's urine-based Alzheimer's diagnostic test, which analyzes urinary volatile organic compounds via mass spectroscopy and machine learning. The designation is TOBY's third, expanding its portfolio across oncology and CNS disease. The company plans to continue clinical validation and work toward future regulatory submissions.NewsfileJ2 Metals Inc. Announces Closing of Flow-Through Private PlacementJ2 Metals closed the second tranche of its flow-through private placement, issuing 1,017,143 shares at $0.35 each for $356,000 in gross proceeds. Combined with the first tranche, the company raised $834,000 total. Net proceeds will explore the Miniac Project and for general corporate purposes.PR NewswireTOBY Receives FDA Breakthrough Device Designation for Its Urine-Based Multi-Cancer Early Detection (MCED) TestTOBY, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company's urine-based Multi-Cancer Early Detection (MCED) test for cancer screening. The designation, the first granted to a urine-based MCED technology, recognizes the test's potential to enable earlier, non-invasive detection of multiple cancers from a single urine sample using spectroscopy and machine learning analysis of volatile organic compounds. The company will now work closely with the FDA to accelerate clinical validation and generate evidence for regulatory submissions and broader clinical adoption.The GuardianContractor that cut back ancient oak in London park identifiedA mystery contractor called Ground Control has been identified as the company that chainsawed an ancient 500-year-old oak tree in Whitewebbs Park, Enfield, north London, for the Toby Carvery restaurant chain owned by Mitchells & Butlers Retail (MBR). The felling, done without council permission, has been disputed by tree experts who found the tree was healthy and showed little sign of needing to be felled, with MBR claiming it was advised the tree was diseased and dangerous. Enfield council has started legal action to evict Toby Carvery, and the controversy is connected to Tottenham Hotspur's plans for a women's football training academy on adjacent land, with a judicial review granted against the planning permission.PR NewswireTOBY Appoints Healthcare Industry Leader Dan Collins as Advisor to the BoardTOBY, Inc. announced the appointment of Dan Collins, a healthcare industry leader with over 25 years of experience, as Advisor to the Board of Directors. Collins, who previously scaled GenesisCare from a single cardiology clinic to a global network serving over 400,000 patients annually with a $5 billion enterprise value, will advise on corporate growth, fundraising, and commercialization strategies. His appointment comes as TOBY progresses toward commercializing its urine-based volatile organic compound test for early multi-cancer detection.